DE60014136D1 - Sapogenin derivate zur behandlung von kognitiven störungen - Google Patents

Sapogenin derivate zur behandlung von kognitiven störungen

Info

Publication number
DE60014136D1
DE60014136D1 DE60014136T DE60014136T DE60014136D1 DE 60014136 D1 DE60014136 D1 DE 60014136D1 DE 60014136 T DE60014136 T DE 60014136T DE 60014136 T DE60014136 T DE 60014136T DE 60014136 D1 DE60014136 D1 DE 60014136D1
Authority
DE
Germany
Prior art keywords
sapogenine
derivatives
cognitive disorders
treating cognitive
stereoisomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60014136T
Other languages
English (en)
Other versions
DE60014136T2 (de
Inventor
Paul Barraclough
Jim Hanson
Phil Gunning
Daryl Rees
Zongqin Xia
Yaer Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phytopharm Ltd
Original Assignee
Phytopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phytopharm Ltd filed Critical Phytopharm Ltd
Application granted granted Critical
Publication of DE60014136D1 publication Critical patent/DE60014136D1/de
Publication of DE60014136T2 publication Critical patent/DE60014136T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
DE60014136T 1999-09-29 2000-09-29 Sapogenin derivate zur behandlung von kognitiven störungen Expired - Fee Related DE60014136T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9923077 1999-09-29
GBGB9923077.3A GB9923077D0 (en) 1999-09-29 1999-09-29 Sapogenin derivatives and their use
PCT/GB2000/003745 WO2001023407A1 (en) 1999-09-29 2000-09-29 Sapogenin derivatives and their use in the treatment of cognitive dysfunction

Publications (2)

Publication Number Publication Date
DE60014136D1 true DE60014136D1 (de) 2004-10-28
DE60014136T2 DE60014136T2 (de) 2005-10-06

Family

ID=10861838

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60014136T Expired - Fee Related DE60014136T2 (de) 1999-09-29 2000-09-29 Sapogenin derivate zur behandlung von kognitiven störungen

Country Status (14)

Country Link
US (2) US20020183294A1 (de)
EP (2) EP1224206B1 (de)
JP (1) JP2003510333A (de)
CN (2) CN1377367A (de)
AT (1) ATE277072T1 (de)
AU (1) AU7538200A (de)
BR (1) BR0014355A (de)
CA (1) CA2385410C (de)
DE (1) DE60014136T2 (de)
ES (1) ES2228608T3 (de)
GB (1) GB9923077D0 (de)
HK (1) HK1045526B (de)
MX (1) MXPA02003306A (de)
WO (1) WO2001023407A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923076D0 (en) 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
ATE424211T1 (de) * 2002-03-27 2009-03-15 Phytopharm Plc Therapeutische verwendung von sapogeninen
PT1490071E (pt) * 2002-03-27 2009-05-25 Phytopharm Plc Métodos terapêuticos e utilizações de sapogeninas e seus derivados
CA2477787C (en) * 2002-03-27 2011-12-20 Phytopharm Plc Therapeutic methods and uses of sapogenins and their derivatives
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0409567D0 (en) 2004-04-28 2004-06-02 Phytopharm Plc Chemical compounds
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
GB0513883D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Diagnosis of Atherosclerosis
EP2073637A4 (de) * 2006-11-20 2011-12-28 Satori Pharmaceuticals Inc Zur behandlung von neurodegenerativen erkrankungen geeignete verbindungen
WO2008136863A2 (en) 2006-11-20 2008-11-13 Satori Pharmaceuticals, Inc. Synthesis of compounds useful as modulators of amyloid-beta production
AU2010207597A1 (en) 2009-01-24 2011-08-18 Phytopharm Plc Treatment of neurotrophic factor mediated disorders
EP2411028B9 (de) * 2009-03-27 2019-11-20 Moleac Pte Ltd. Therapie zur förderung von zellwachstum
US20130210786A1 (en) 2010-07-20 2013-08-15 Patrick Alexander Howson Treatment of l-dopa, dopamine agonist and/or dopamine enhancer induced disorders
CU20110244A7 (es) * 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
US11319338B2 (en) * 2012-04-03 2022-05-03 Goldporp Pharma Limited Timosaponin compounds
CN102924559B (zh) * 2012-11-16 2015-10-28 沈阳药科大学 菝葜皂苷元衍生物及其制备和应用
CN108264535A (zh) * 2016-12-30 2018-07-10 中国科学院上海药物研究所 一种抗抑郁化合物及其制备方法和应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2299758A (en) * 1940-08-03 1942-10-27 Parke Davis & Co Sapogenin derivative and preparation of the same
BE794362A (fr) * 1972-01-22 1973-07-23 Merck Patent Gmbh Sulfates hydrosolubles de sterine
US3929769A (en) * 1972-05-19 1975-12-30 Ciba Geigy Corp Process for the manufacture of steroid epoxides
CA985172A (en) * 1972-10-06 1976-03-09 Dushan M. Dvornik Compositions and methods for reducing blood cholesterol
DE2416978A1 (de) * 1974-04-08 1975-10-09 Degussa Arzneimittel mit dem hauptsapogenin der helleborus-arten als wirkstoff
LU81256A1 (fr) * 1979-05-15 1980-12-16 Oreal Composition cosmetique capillaire notamment pour le lavage et/ou le demelage des cheveux,a base d'un extrait de plantes contenant des saponosides
JPS5855500A (ja) * 1981-09-25 1983-04-01 Tokiwa Yakuhin Kogyo Kk １６−デヒドロプレグネノロンの製造法
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4562250A (en) * 1982-09-13 1985-12-31 Regents Of The University Of Minnesota Steroidal glycosides produced by Yucca tissue culture
US4546097A (en) * 1983-11-04 1985-10-08 The United States Of America As Represented By The Department Of Health And Human Services Saponin-based polyether polyols, pharmaceutical compositions and a method of using same
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
US5017562A (en) * 1987-02-11 1991-05-21 Regents Of The University Of Minnesota Crystalline saponin-containing complex
DE3838716A1 (de) * 1988-11-15 1990-05-17 Kanoldt Arzneimittel Gmbh Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie
SG50585A1 (en) * 1990-01-18 1998-07-20 Cura Nominees Pty Ltd Glycoalkaloids
US5252729A (en) * 1991-10-23 1993-10-12 Schering Corporation Extraction of compounds from plant materials using supercritical fluids
US5244887A (en) * 1992-02-14 1993-09-14 Straub Carl D Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof
JPH05246866A (ja) * 1992-03-06 1993-09-24 Ruibosuteii Japan:Kk 脳代謝促進・脳機能改善剤
WO1994000480A1 (en) * 1992-06-26 1994-01-06 Pfizer Inc. Steroidal glycosides for treating hypercholesterolemia
DE4303214A1 (de) * 1993-02-04 1994-08-11 Wolfgang Marks Behandlung von Erkrankungen viraler, viroidaler oder onkogener Genese durch Steroid-Saponine oder deren Aglykone
CZ280195A3 (en) * 1993-04-28 1996-02-14 Pfizer Crystalline spirostanyl glycoside, monohydrate thereof, pharmaceutical composition based thereon and process for preparing crystalline steroidal glycoside
CN1033754C (zh) * 1993-05-31 1997-01-08 上海第二医科大学 知母皂甙元作为制备β肾上腺素和M胆碱受体双向调节药的用途及其制法
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
AU7948494A (en) * 1993-12-28 1995-07-17 Pfizer Inc. Steroidal glycosides
EP0737202A1 (de) * 1993-12-28 1996-10-16 Pfizer Inc. Hypocholesterolemische mittel
US5856535A (en) * 1994-08-18 1999-01-05 Magainin Pharmaceuticals, Inc. Aminosterol ester compounds
US5840740A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds and a method of treating infection using the aminosterol compounds
PL318937A1 (en) * 1994-08-30 1997-07-21 Pfizer Spirostanyloglycoside crystals
CA2200436A1 (en) * 1994-09-20 1996-04-04 Pfizer Inc. Combination therapy for hypercholesterolemia
US6150336A (en) * 1995-05-29 2000-11-21 Pfizer Inc. Steroidal glycosides
US5847172A (en) * 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5840936A (en) * 1995-06-07 1998-11-24 Magainin Pharmaceuticals Inc. Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE)
US6143738A (en) * 1995-06-07 2000-11-07 Magainin Pharmaceuticals, Inc. Therapeutic uses for an aminosterol compound
US5763430A (en) * 1995-06-07 1998-06-09 Magainin Pharmaceuticals Inc. Method of treating a viral infection by administering a steroid compound
US5795885A (en) * 1995-06-07 1998-08-18 Magainin Pharmaceuticals Inc. Method of inhibiting profileration of cells by administering an aminosterol compound
US5792635A (en) * 1995-06-07 1998-08-11 Magainin Pharmaceuticals, Inc. Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine
WO1997013766A1 (fr) * 1995-10-13 1997-04-17 Banyu Pharmaceutical Co., Ltd. Derives heteroaromatiques substitues
US5726179A (en) * 1996-04-01 1998-03-10 The University Of Toledo Muscarinic agonists
DE69731473T2 (de) * 1996-05-09 2005-10-27 Amrad Operations Pty. Ltd., Richmond Verwendung von steroiden zur behandlung von asthma und atemwegerkrankungen
US5804239A (en) * 1996-07-26 1998-09-08 Nouveau Technologies, Inc. Method and composition for food flavoring
CN1131237C (zh) * 1997-09-26 2003-12-17 中国人民解放军军事医学科学院放射医学研究所 甾体皂甙防治老年性痴呆的用途及新的甾体皂甙
JP3873097B2 (ja) * 1997-11-06 2007-01-24 独立行政法人理化学研究所 抗肥満剤及び脂質代謝改善剤
DE69929177T2 (de) * 1998-03-26 2006-08-24 Phytopharm Plc, Godmanchester Smilagenin und anzurogenin-d zur behandlung der alzheimerischen krankheit
GB9905275D0 (en) * 1999-03-08 1999-04-28 Phytopharm Ltd Treatment of conditions associated with membrane-bound receptors and their function
GB2347676A (en) * 1999-03-08 2000-09-13 Phytopharm Plc Screening method
US6544566B1 (en) * 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
BR0001794A (pt) * 2000-05-15 2001-12-26 Laboratorios Biosintetica Ltda Aplicação de fitosteróides (e seus isÈmeros), ácidofólico, cianocobalamina e piridoxina em fibrasdietéticas (alimentares)
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives

Also Published As

Publication number Publication date
GB9923077D0 (en) 1999-12-01
CA2385410C (en) 2008-05-20
EP1224206B1 (de) 2004-09-22
HK1045526A1 (en) 2002-11-29
DE60014136T2 (de) 2005-10-06
US20020183294A1 (en) 2002-12-05
JP2003510333A (ja) 2003-03-18
US20080021004A1 (en) 2008-01-24
BR0014355A (pt) 2002-07-16
EP1548025A2 (de) 2005-06-29
EP1548025A3 (de) 2008-11-19
HK1045526B (zh) 2005-04-22
CN101143147A (zh) 2008-03-19
CA2385410A1 (en) 2001-04-05
MXPA02003306A (es) 2002-10-04
AU7538200A (en) 2001-04-30
WO2001023407A1 (en) 2001-04-05
ATE277072T1 (de) 2004-10-15
CN1377367A (zh) 2002-10-30
ES2228608T3 (es) 2005-04-16
EP1224206A1 (de) 2002-07-24

Similar Documents

Publication Publication Date Title
DE60014136D1 (de) Sapogenin derivate zur behandlung von kognitiven störungen
CY1107475T1 (el) Αναστολεις ρο-κινασης
DK1353672T3 (da) Syntese af 4-amino-thalidomidenantiomerer
DE60027913D1 (de) 5-beta-sapogenin und pseudosapogeninderivate und ihre verwendung zur behandlung von demenz
ATE515513T1 (de) Behandlung von fibrose durch antagonismus zwischen il-13 und il-13-rezeptorketten
MY136270A (en) Processes and intermediates for preparing anti-cancer compounds
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ES2194960T3 (es) N-(2-sustituido-3-(2-aminoetil)-1h-indol-5-il)-amidas como nuevos agonistas de 5-ht1f.
EA200300807A1 (ru) Лечение нарушений центральной нервной системы с использованием антагонистов оксидазы d-аминокислот и d-аспартатоксидазы
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
WO2003057213A3 (en) Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
ATE255094T1 (de) Piperazinderivate zur behandlung der niedrigen harnwege
ATE402704T1 (de) Dopamin-d3-rezeptor-liganden zur behandlung von sucht
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
ATE256126T1 (de) 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
DE60142304D1 (de) Substituierte heterocyclische verbindungen und deren verwendung zur behandlung multipler medikamentenresistenz
ATE297926T1 (de) Hexahydropyrazino(1'2':1,6)-pyrido(3,4-b)indole 1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
YU22802A (sh) Izonipekotamidi za lečenje poremećaja nastalih posredstvom integrina
DE69810340D1 (de) Naphtho-imidazo(1,2-a)pyridin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems
ATE319709T1 (de) Indolderivate zur behandlung von depression und angstzuständen
ATE283269T1 (de) 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems
ATE289510T1 (de) Sulfonylpyridazinone derivate zur behandlung von ischämischem gewebeschaden
DE602004010186D1 (de) Diazaspiropiperidinderivate als inhibitoren von glycintransporter 1 und glycintransporter 2
NO20012538L (no) Anvendelse av N-substituerte azabicycloalkanderivater for behandling av forstyrrelser i sentralnervesystemet

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee